MAGE A3 TCR

N/A

Report date: 2022/03/03 17:33:53

Base Information

Drug NameMAGE A3 TCR

Drug Alias NameAnti-MAGE-A3-TCRAnti-MAGE A3 HLA-A-01-restricted TCRAnti-MAGE-A3-DP4-TCRMAGE-A3-TCR

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionGene transferenceMelanoma-associated antigen 3 modulators

TargetsMelanoma-associated antigen 3

Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesKite Pharma National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma National Cancer Institute

Inactive CompaniesN/A

Active IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[7]

Inactive IndicationsN/A

Other Information

ATC CodeN/A